ARCH-backed start­up Met­sera launch­es with $290M to take on obe­si­ty gi­ants

A new start­up aims to chal­lenge No­vo Nordisk and Eli Lil­ly’s du­op­oly atop to­day’s mar­ket for obe­si­ty drugs.

The start­up Met­sera of­fi­cial­ly launched Thurs­day, an­nounc­ing $290 mil­lion in an ini­tial fi­nanc­ing to ad­vance mul­ti­ple ex­per­i­men­tal weight loss drugs in­to the clin­ic.

Many de­tails on Met­sera’s clin­i­cal strat­e­gy, which will test com­bi­na­tions of var­i­ous drugs, re­main close­ly-guard­ed se­crets. But Met­sera’s lead as­set is a GLP-1 ag­o­nist now in the clin­ic in the US, CEO Clive Mean­well said, with ad­di­tion­al pro­grams not far be­hind. The team is run­ning head-to-head non-clin­i­cal and ear­ly clin­i­cal stud­ies against Ozem­pic and Moun­jaro, and plans to ran­dom­ize its Phase 1/2 pro­grams in that same man­ner.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER